| Revenue Growth | Limb Reconstruction 9%, Therapeutic Solutions 4%, Global Spine -1%, US Spine -5%. |
|---|---|
| Mgmt Confidence | Cautious; acknowledged Q3 results were below expectations and supply chain issues persist. |
| Demand Visibility | Limited; cited unplanned supplier delays and inventory constraints impacting top 30 distributors. |
| Margin Trends | Adjusted gross margin 70.7%; EBITDA margin 12.5% vs 12.1% prior year. |
| Op. Leverage | Reduced operating leverage noted due to lower spine revenue and unfavorable mix. |
| Vol vs Price | Therapeutic Solutions saw 4% volume growth; Spine growth impacted by inventory constraints. |
| Segment Growth | Limb Reconstruction outperforming at 9%; US Spine Fixation lagging at -5%. |
| New Clients | Concentrating resources on top distributors generating 80% of US spinal implant revenue. |
| Capex & Debt | Ended quarter with $86.9M cash; inventory investment ahead of Bharata launch. |
| Regulatory | Two 510K clearances for 7D navigation; $22M 2027 headwind from European MDR. |
| Commentary | Strategy focuses on simplifying portfolio and exiting non-strategic, lower-performing distributor relationships. |
| New Launches | Full market launch of Bharata spinal implant system expected in Q4 2026. |
Growth
Reported net sales of $207.9M, up 2.3% year-over-year; Limb Reconstruction grew 9% constant currency.
Outlook
Full-year 2026 revenue guidance lowered to $825M-$830M; $22M MDR headwind expected in 2027.
Risks
Management pivoted to vague 'market softness' language when pressed on market share loss versus procedural declines.
The company's earnings call, NASDAQ: OFIX, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Orthofix Medical Inc.: key numbers
- Share price
- $6.80Close, Nov 16
- Market cap
- $277M
- Shares outstanding
- 40.76MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Orthofix Medical Inc.
All →Orthofix Medical Insider Juniper Investment Company LLC Buys $5.11M of Stock
Juniper Investment Company LLC bought 689,803 shares of Orthofix Medical Inc. at $7.04 to $7.41 a share (average $7.40) in 2 transactions, worth $5.11M in total between Nov 9, 2026 and Nov 11, 2026. Shares held after the trade: 4,461,019 (+0.3%).
- Value
- $5.11M
- Shares
- 689,803
- Average price
- $7.40
- Holding change
- +0.3%
- Trade date
- Nov 9, 2026 to Nov 11, 2026
Orthofix Medical Q3 2026 Results: Net Loss of $6.07M, Loss Narrows
Orthofix Medical Inc. reported net sales of $207.9 million for the third quarter of 2026, a slight increase from $205.6 million in the prior year period. The company achieved a quarterly operating income of $1.5 million, a significant improvement from the $17.0 million operating loss in Q3 2025, though it still recorded a net loss of $6.1 million for the quarter.
- Key figure
- Net loss $6.07M
Orthofix Medical Financial Results
Orthofix Medical reported Q3 2026 net sales of $207.9 million, a 1% increase over the prior year, and a net loss of $6.1 million. The company revised its full-year 2026 revenue guidance downward to $825M-$830M to reflect weaker performance in its U.S. Spine business and ongoing efforts to improve commercial execution.
- Term
- Q3 2026
“Continued growth in Limb Reconstruction and Therapeutic Solutions helped offset weaker Spine performance. In U.S. Spine, we are accelerating actions to strengthen commercial execution, improve instrument set supply and allocation, and increase asset productivity by focusing resources on our highest-performing distributor partners, products and market opportunities.”
Massimo Calafiore, President and Chief Executive Officer